We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.


Galapagos Enters Three-year Collaboration with Roche

Listen with
Register for free to listen to this article
Thank you. Listen to this article using the player above.

Want to listen to this article for FREE?

Complete the form below to unlock access to ALL audio articles.

Read time: Less than a minute

Galapagos NV has announced that Galapagos' service division, BioFocus, has entered into three-year collaboration with Roche. This agreement builds on the working history between Roche and BioFocus.
Under the terms of the agreement, BioFocus will supply Roche with exclusive chemical compound libraries. 

BioFocus will synthesize chemical compound libraries based on Roche's framework structures and provide these collections on an exclusive basis to Roche. 

These libraries will be generated using a combination of BioFocus' molecular informatics tools and a wide range of synthetic chemistry capabilities. 
BioFocus designs and synthesizes both exclusive as well as non-exclusive (SoftFocus®) chemical compound libraries that can be used in drug discovery programs, including hit finding, lead optimization and patent exemplification.
"We are very pleased with this new agreement to deliver exclusive compound libraries to complement Roche's drug discovery programs," said Onno van de Stolpe, CEO of Galapagos. 

"With a strong set of design tools and world-class synthetic chemistry capabilities, BioFocus continues to secure new business by providing high-quality libraries to the pharmaceutical and biotech industries."